News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Can-Fite BioPharma (CFBI) To Present At The 9th International Congress Of Autoimmunity

3/25/2014 7:00:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PETACH TIKVA, Israel, March 25, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.

On Friday March 28th, 16:30, Can-Fite CEO Dr. Pnina Fishman will Co-Chair the session of Psoriatic Arthritis, Rheumatoid Arthritis and Ankylosing Spondylitis and deliver a presentation on: 'The A3 adenosine receptor as a therapeutic target and predictive marker in Rheumatoid Arthritis.' In the frame of the presentation Dr. Fishman will present positive data from the recently concluded Phase II Rheumatoid Arthritis and the interim analysis of the Phase II/III Psoriasis studies.

CF101 recently announced a successfully completed Phase II trial data and is set for Phase III of clinical trial testing in the U.S., Europe and Israel. Rheumatoid arthritis is an autoimmune disease and according to WebMD affects about 1% of the American population and millions more around the world. Rheumatoid arthritis is two to three times more common in women than men. According to independent business information provider Visiongain, the global rheumatoid arthritis (RA) drug market is predicted to generate revenues of $38.5 billion in 2017.

"We are excited to be a part of the conference and share our scientific findings and talk about our initiatives for the coming months and our plans for the Phase III Rheumatoid Arthritis study," says Can-Fite CEO Dr. Pnina Fishman. "Combating autoimmune diseases such as rheumatoid arthritis and developing treatments with CF101 have been our goal that is coming to fruition. The conference is a great venue to share research findings, collaborate, share best practices with our peers and learn from one another with a goal of fighting autoimmune diseases."

To arrange a one-on-one meeting with management, please contact Robert Haag at or 1-866-976-4784.

About 9th International Congress On Autoimmunity
The 9th International Congress on Autoimmunity is the world's foremost gathering of top experts in immunology, rheumatology, and related fields. First established by renowned autoimmunity expert Professor Yehuda Shoenfeld, the congress will address the genetic, etiology, diagnostic, clinical aspects and novel therapies of 80 autoimmune diseases. Join your colleagues in breathtaking Nice, France, on March 26-30, 2014 and learn about the newest therapeutic techniques and diagnostic tools. Previous meetings were comprised of 81 symposia featuring 600 leading speakers.

About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the "TASE") (TASE: CFBI). Level II American Depository Receipts of the Company currently trade on the NYSE MKT (NYSE MKT: CANF). Can-Fite, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys in Israel. Dr. Fishman serves as the Chief Executive Officer of Can-Fite. Dr. Fishman founded Can-Fite on the basis of her scientific findings, and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular, ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and the A3AR is developed as a biological predictive marker. Can-Fite's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis and psoriasis. Can-Fite's CF102 drug candidate is being developed for the treatment of liver diseases and CF602 is being developed for the treatment of inflammation and sexual dysfunction. To date, more than 700 patients have participated in clinical trials conducted by Can-Fite. Can-Fite previously spun off its activity in the ophthalmic field to OphthaliX Inc., in which it holds 82%, and is currently listed on the U.S. Over-the-Counter Markets (OTCQB: OPLI).

Forward-Looking Statements

This press release contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the "SEC"), press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.


IRTH Communications
Robert Haag

SOURCE Can-Fite BioPharma Ltd.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus